Novo’s Ozempic gains MACE risk reduction label in USNovo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a Share XNovo’s Ozempic gains MACE risk reduction label in UShttps://pharmaphorum.com/news/novos-ozempic-gains-mace-risk-reduction-label-in-us/
Lilly targets quarterly deals worth up to $5bn to boost R&DEli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as Share XLilly targets quarterly deals worth up to $5bn to boost R&Dhttps://pharmaphorum.com/news/lilly-targets-quarterly-deals-worth-up-to-5bn-boost-rd/
Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Lilly claims another victory in Alimta patent defenceEli Lilly ended 2019 with a win in its long-running legal battle to prevent generics of its big-selling Share XLilly claims another victory in Alimta patent defencehttps://pharmaphorum.com/news/lilly-claims-another-victory-in-alimta-patent-defence/
Lilly doubles down on Dexcom tech for connected insulin devicesTwo years ago, Eli Lilly started working with Dexcom to integrate continuous glucose monitoring (CGM) into its insulin Share XLilly doubles down on Dexcom tech for connected insulin deviceshttps://pharmaphorum.com/news/lilly-doubles-down-on-dexcom-tech-for-connected-insulin-devices/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
Lilly and Boehringer rejig diabetes alliance as Jardiance soarsEli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on Share XLilly and Boehringer rejig diabetes alliance as Jardiance soarshttps://pharmaphorum.com/news/lilly-and-boehringer-rejig-diabetes-alliance-as-jardiance-soars/
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritisBeating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting Share XNovartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritishttps://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Lilly’s new drugs offset slumping sales of erectile dysfunction pill Cialis in Q3Eli Lilly upped its guidance for 2019 after posting strong third quarter results, as more recently released drugs Share XLilly’s new drugs offset slumping sales of erectile dysfunction pill Cialis in Q3https://pharmaphorum.com/news/lillys-new-drugs-offset-slumping-sales-of-erectile-dysfunction-drug-cialis-in-q3/
